488 related articles for article (PubMed ID: 29309431)
41. Effects of pituitary pars intermedia dysfunction and Prascend (pergolide tablets) treatment on endocrine and immune function in horses.
Miller AB; Loynachan AT; Bush HM; Hart KA; Barker VD; Campana-Emard AG; Grubbs ST; Adams AA
Domest Anim Endocrinol; 2021 Jan; 74():106531. PubMed ID: 32942194
[TBL] [Abstract][Full Text] [Related]
42. BEVA primary care clinical guidelines: Diagnosis and management of equine pituitary pars intermedia dysfunction.
Menzies-Gow NJ; Banse HE; Duff A; Hart N; Ireland JL; Knowles EJ; McFarlane D; Rendle D
Equine Vet J; 2024 Mar; 56(2):220-242. PubMed ID: 37795557
[TBL] [Abstract][Full Text] [Related]
43. Seasonal changes in plasma adrenocorticotropic hormone and α-melanocyte-stimulating hormone in response to thyrotropin-releasing hormone in normal, aged horses.
Funk RA; Stewart AJ; Wooldridge AA; Kwessi E; Kemppainen RJ; Behrend EN; Zhong Q; Johnson AK
J Vet Intern Med; 2011; 25(3):579-85. PubMed ID: 21457320
[TBL] [Abstract][Full Text] [Related]
44. Pro-opiomelanocortin and adrenal function.
Bicknell AB; Savva D; Lowry PJ
Endocr Res; 1996 Nov; 22(4):385-93. PubMed ID: 8969887
[TBL] [Abstract][Full Text] [Related]
45. Differential gene expression profiles of POMC-related enzymes, transcription factors and receptors between non-pituitary and pituitary ACTH-secreting tumors.
Tani Y; Sugiyama T; Izumiyama H; Yoshimoto T; Yamada S; Hirata Y
Endocr J; 2011; 58(4):297-303. PubMed ID: 21383526
[TBL] [Abstract][Full Text] [Related]
46. The melanocortin receptor subtypes in chicken have high preference to ACTH-derived peptides.
Ling MK; Hotta E; Kilianova Z; Haitina T; Ringholm A; Johansson L; Gallo-Payet N; Takeuchi S; Schiöth HB
Br J Pharmacol; 2004 Nov; 143(5):626-37. PubMed ID: 15466451
[TBL] [Abstract][Full Text] [Related]
47. Dietary sodium modulates mRNA abundance of enzymes involved in pituitary processing of proopiomelanocortin.
Chandramohan G; Ni XP; Kalinyak JE; Humphreys MH
Pituitary; 2001 Sep; 4(4):231-7. PubMed ID: 12501973
[TBL] [Abstract][Full Text] [Related]
48. Correlation of pituitary histomorphometry with adrenocorticotrophic hormone response to domperidone administration in the diagnosis of equine pituitary pars intermedia dysfunction.
Miller MA; Pardo ID; Jackson LP; Moore GE; Sojka JE
Vet Pathol; 2008 Jan; 45(1):26-38. PubMed ID: 18192571
[TBL] [Abstract][Full Text] [Related]
49. 60 YEARS OF POMC: Purification and biological characterisation of melanotrophins and corticotrophins.
Lowry P
J Mol Endocrinol; 2016 May; 56(4):T1-T12. PubMed ID: 26643914
[TBL] [Abstract][Full Text] [Related]
50. Decreased hypothalamic prohormone convertase expression in huntington disease patients.
van Wamelen DJ; Aziz NA; Zhao J; Balesar R; Unmehopa U; Roos RA; Swaab DF
J Neuropathol Exp Neurol; 2013 Dec; 72(12):1126-34. PubMed ID: 24226266
[TBL] [Abstract][Full Text] [Related]
51. Prevalence, risk factors and clinical signs predictive for equine pituitary pars intermedia dysfunction in aged horses.
McGowan TW; Pinchbeck GP; McGowan CM
Equine Vet J; 2013 Jan; 45(1):74-9. PubMed ID: 22594955
[TBL] [Abstract][Full Text] [Related]
52. Expression of the prohormone convertase PC2 correlates with the presence of corticotropin-like intermediate lobe peptide in human adrenocorticotropin-secreting tumors.
Vieau D; Seidah NG; Mbikay M; Chrétien M; Bertagna X
J Clin Endocrinol Metab; 1994 Nov; 79(5):1503-6. PubMed ID: 7962350
[TBL] [Abstract][Full Text] [Related]
53. Immunocytochemical demonstration of proopiomelanocortin-derived peptides in pituitary adenomas of the pars intermedia in horses.
Heinrichs M; Baumgärtner W; Capen CC
Vet Pathol; 1990 Nov; 27(6):419-25. PubMed ID: 2177580
[TBL] [Abstract][Full Text] [Related]
54. Regulation and secretion of proopiomelanocortin peptides from isolated perifused dog pituitary pars intermedia cells.
Kemppainen RJ; Zerbe CA; Sartin JL
Endocrinology; 1989 May; 124(5):2208-17. PubMed ID: 2539971
[TBL] [Abstract][Full Text] [Related]
55. Comparison of cortisol and ACTH responses after administration of thyrotropin releasing hormone in normal horses and those with pituitary pars intermedia dysfunction.
Beech J; Boston R; Lindborg S
J Vet Intern Med; 2011; 25(6):1431-8. PubMed ID: 22092639
[TBL] [Abstract][Full Text] [Related]
56. The use of adrenocorticotrophic hormone as a potential biomarker of pituitary pars intermedia dysfunction in horses.
Lee ZY; Zylstra R; Haritou SJ
Vet J; 2010 Jul; 185(1):58-61. PubMed ID: 20537574
[TBL] [Abstract][Full Text] [Related]
57. [The intermediate lobe of the pituitary, model of neuroendocrine communication].
Lamacz M; Tonon MC; Louiset E; Cazin L; Vaudry H
Arch Int Physiol Biochim Biophys; 1991 Jun; 99(3):205-19. PubMed ID: 1717055
[TBL] [Abstract][Full Text] [Related]
58. Post-translational processing of pro-opiomelanocortin (POMC)-derived peptides during fetal monkey pituitary development. I. Adrenocorticotropin (ACTH) and alpha-melanotropins (alpha-MSHs).
Allen RG; Hatfield JM; Stack J
Dev Biol; 1988 Mar; 126(1):156-63. PubMed ID: 2830157
[TBL] [Abstract][Full Text] [Related]
59. The effects of sample handling and N-phenylmaleimide on concentration of adrenocorticotrophic hormone in equine plasma.
Rendle DI; Litchfield E; Gough S; Cowling A; Hughes KJ
Equine Vet J; 2015 Sep; 47(5):587-91. PubMed ID: 24980684
[TBL] [Abstract][Full Text] [Related]
60. Human mast cells in the neurohormonal network: expression of POMC, detection of precursor proteases, and evidence for IgE-dependent secretion of alpha-MSH.
Artuc M; Böhm M; Grützkau A; Smorodchenko A; Zuberbier T; Luger T; Henz BM
J Invest Dermatol; 2006 Sep; 126(9):1976-81. PubMed ID: 16675966
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
